Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Hodgkin Lymphoma through trial conditions or approval indications mapped to it or to one of its descendant entities.
5 drugs · 58 active trials
6 drugs · 92 active trials
Outside the funnel: Phase not stated 2. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tagraxofusp | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Nov 11, 2022 |
| Zoledronic Acid | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 12, 2016 |
| Dasatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 4 | 0 | — | — | 2008-10 |
| Belinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | 2006-03 |
| Nab-paclitaxel | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | 2013-09 |
| Alisertib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Apr 16, 2012 |
| Capecitabine | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-06 |
| Copanlisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Mar 27, 2018 |
| Irinotecan | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 1999-01 |
| O6-Benzylguanine | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2015-02 |
| Olaparib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Sep 13, 2019 |
| Sunitinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2009-08 |
| Abemaciclib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Abiraterone | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Afatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Alvespimycin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-07 |
| Bicalutamide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Bone Marrow Transplantation | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-08 |
| Cabazitaxel | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Cabozantinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Cediranib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-05 |
| Celecoxib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Cobimetinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Conatumumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-02 |
| Dabrafenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Darolutamide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Durvalumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Duvelisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 18, 2021 |
| Enasidenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Entrectinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Enzalutamide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Erlotinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Fluorouracil | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| HDAC Inhibitor REC-2282 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 4, 2010 |
| Ibuprofen | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 18, 2020 |
| Imatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Imatinib Mesylate | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2001-08 |
| Lenvatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Lorlatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Neratinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Niacinamide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-06 |
| Obinutuzumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 27, 2018 |
| Paclitaxel | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-07 |
| Palbociclib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Pertuzumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Ponatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Prednisolone | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-07 |
| Regorafenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Selinexor | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 8, 2021 |
| Sorafenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.